pemigatinib
incyte,specialised therapeutics
#wcgic2022 #hpbcsm
final results of fight202 ph2 pemigatinib in pretreated cca with fgfr2 fusions orr 37% dor 9 mos os 17.8 mos we need to profile ccas - incidence 10-15%
unfortunately still no path to funding in yet 
Cancer Doctor, Professor, Lifelong Learner  #GIcancer ???? @UBC @BCCancer @CCTG #Prez @CAMO #TEDxSpeaker #MedTwitter Tweets are my own